# Core 3: MPIP.

> **NIH NIH P01** · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $258,755

## Abstract

CORE 3_MULTIPARAMETER IMAGING AND PATHOLOGY: SUMMARY/ABSTRACT
One basic function of Core 3 includes the collection and distribution of specimens and patient samples to P01
investigators. Importantly, we have been acquiring blood and tissue samples from most diffuse large B cell
lymphoma (DLBCL) patients treated with standard of care therapy at MDACC since 2007 and at WCMC since
1993. The two hematopathologists co-directing this core (Drs. Patel and Vega) will ensure proper tissue
collection, provide pathologic characterization of all lymphoma tumors, and will work closely with the project
investigators to address the needs of the projects. In addition, Core 3 has developed methods in both institutions
to ensure the optimal utilization of limited tissue resources by creating tissue derivatives (e.g. tissue microarrays,
RNA, DNA) that can serve multiple P01 projects. These tissue derivatives are suitable for the identification and
validation of molecular markers that may contribute to lymphoma progression and disease resistance. These
tissue resources will also facilitate establishing relevant clinical correlation necessary for prognostication and
identification of new biomarkers and novel therapeutic targets.
The use of common specimens among multiple projects requires the services of an information system to contain
and organize results of tests performed on a given sample so that duplication of assays is avoided, and
multidisciplinary interactions are facilitated. Therefore, Core 3 is also responsible for generating a data repository
for all biospecimens collected, in collaboration with Core 1 (Lymphoma Model Systems) and Core 2 (Biostatistics
and Computational Biology), the information in which provides a detailed characterization of clinically annotated
tissue samples. The bank is fully annotated and linked to a lymphoma outcomes database in both institutions
that captures information on basic demographics, diagnosis, clinical prognostic factors, treatment history, and
treatment outcome for each patient. This allows selecting samples with any combination of molecular,
cytogenetic, immunophenotypic, clinical, and response data for laboratory studies.
In addition to providing the infrastructure for a uniform pathology review and classification of clinical specimens
used in the P01 projects - using conventional histomorphologic, immunohistochemical and molecular techniques
and generating a pathology image library available to all P01 investigators at both institutions - Core 3 will also
develop and provide a variety of imaging services critical to successful molecular analysis of mouse and human
LBCL. To this end, the Core 3 will perform routine and highly multiplexed immunohistochemical (IHC) and
immunofluorescence (IF) staining, and spatial transcriptomic profiling, with state-of-the-art technology.
Core 3 incorporates several innovative features including a secure database shared by both institutions
comprising comprehensive diagnostic patholo...

## Key facts

- **NIH application ID:** 10847994
- **Project number:** 1P01CA272295-01A1
- **Recipient organization:** WEILL MEDICAL COLL OF CORNELL UNIV
- **Principal Investigator:** Sanjay Shutish Patel
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $258,755
- **Award type:** 1
- **Project period:** 2024-08-12 → 2029-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10847994

## Citation

> US National Institutes of Health, RePORTER application 10847994, Core 3: MPIP. (1P01CA272295-01A1). Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/grant/nih/10847994. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*